Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License To Develop Serpin Pharma's Intravenous Formulation Of SP16 For Cancer Related Pain; Serpin To Receive 382,034 Shares Of DWTX Common Stock And 179.1878 Of Preferred Stock

Author: Benzinga Newsdesk | September 29, 2025 06:17am

Posted In: DWTX